MIRXES-B (02629) surged more than 5% in afternoon trading. At the time of writing, the stock was up 3.44% to HK$52.55, with a turnover of HK$32.73 million.

The company announced it recently signed a memorandum of understanding (MOU) with Yunnan Walvax Biotechnology to establish a strategic partnership focused on building an RNA-centric platform for preventive and precision medicine. The collaboration will cover joint development, clinical trials, regulatory approvals, as well as sales and distribution. The MOU is valid for two years from the signing date.

According to the announcement, the partnership aims to leverage the complementary strengths of both companies to create synergies. MIRXES-B will contribute its advanced RNA diagnostic technology, proprietary Asia-centric disease RNA database, and ASEAN manufacturing and regulatory capabilities—including the region's first Industry 4.0 nucleic acid testing and reagent production base—along with local distribution channels. Walvax will provide its proprietary mRNA vaccine technology, robust clinical pipeline, and top-tier vaccine and therapeutic production infrastructure. Together, the collaboration seeks to establish an integrated R&D and commercial deployment platform for preventive and precision medicine.